Gilead Sciences CEO Daniel O'Day says the company will have sufficient global supply of its coronavirus treatment remdesivir by the end of October, as reported on CNBC.
His remarks came shortly after the publication of peer-reviewed final data from Gilead's large-scale trial of remdesivir, demonstrating that the antiviral helped hospitalized COVID-19 patients recover five days faster on average.
For severely ill patients who received remdesivir, recovery was expedited by seven days.
"The earlier you treat, the better in the hospital and you can prevent people from ever even going onto those stages of the disease where the risk of dying is very high," O'Day said.
To read more NewsPoints articles, click here.